Lilly raises guidance, launches Basaglar

By Paul Bonanos | Dec 15, 2016 | 10:33 PM GMT

Eli Lilly and Co. (NYSE:LLY) announced 2017 guidance in which it expects adjusted EPS of $4.05-$4.15 on revenue of $21.8-$22.3 billion. It expects mid-single-digit revenue growth driven by recent product launches, including diabetes drugs

Read the full 343 word article

How to gain access

Continue reading with a
two-week free trial.